The company is a part of the EU-funded project SEtTReND (Schistosoma Epigenetics – Targets, Regulation, New Drugs) with major focus on drug discovery, dddmag.com reported.
The project involves making new active compounds against the parasitic disease, schistosomiasis.
iNovacia’s inhibitors against the parasitic target protein will be tested directly against the parasites in the next step.